Business Wire

TX-MARY-KAY-INC

14.12.2022 23:42:39 CET | Business Wire | Press release

Share
Mary Kay Inc. Releases 2020 – 2022 Sustainability & Social Impact Report

Mary Kay Inc., a global advocate for corporate social responsibility, today released a report detailing progress on Enriching Lives Today for a Sustainable Tomorrow (ELTFAST), the brand’s global sustainability program.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221214005001/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Enriching Lives Today for a Sustainable Tomorrow extends Mary Kay's vision to 2030 and beyond. (Credit: Mary Kay Inc.)

“We’re proud of the progress we’ve made on our sustainability journey so far, and we are inspired to see how our actions today will address global challenges for future generations,” said Deborah Gibbins, Chief Operating Officer at Mary Kay Inc. “Mary Kay has operations in nearly 35 countries—we consider that an accomplishment and a responsibility. Enriching Lives Today for a Sustainable Tomorrow is our roadmap for supporting our business strategy, reducing our environmental impact, and supporting communities where we operate.”

Enriching Lives Today for a Sustainable Tomorrow extends Mary Kay’s vision to 2030 and beyond. It builds a picture of what good “looks like” for Mary Kay, Independent Beauty Consultants, customers and—most importantly—the planet. Enriching Lives Today for a Sustainable Tomorrow was developed with Mary Kay’s key stakeholders and is aligned with the United Nations’ Sustainable Development Goals, making Mary Kay a key part of a global coalition to ensure a better future.

The 2020 – 2022 full report can be viewed here. An executive summary of the report is available here.

Since the launch of ELTFAST in 2020, Mary Kay has made significant progress toward its goals despite the many challenges presented by the COVID-19 epidemic. The 2022 report details its efforts since 2020—the beginning of its Decade of Action—and serves as a reaffirmation of the company’s drive to deliver sustainable change.

Business Excellence

  • Focusing on nurturing its company culture, Mary Kay garnered 13 employer / great place to work awards and was ranked #8 on list of “The Companies Employees Don’t Want to Leave,” published by Resume.io.
  • Released gender diversity data in leadership: executive team is 54% female, managers and above are 59% female, with 62% of the total workforce being female.
  • In 2021, scored 75% employee engagement, a 6% increase over the 2019 full engagement survey (This is 10% over the global average for employee engagement).
  • 38 company awards in business excellence, social impact, and sustainability.
  • Deloitte named Mary Kay Inc. one of the 2022 U.S. Best Managed Companies.

Product Stewardship

  • Achieved Forest Stewardship Council (FSC) certification (U.S.A only). The FSC certification ensures products come from responsibly managed forests providing environmental, social and economic benefits.
  • 12% of our indirect suppliers are women, minority or veteran-owned (U.S.A. only).
  • Achieved palm oil–88% certified and palm kernel–72% certified.
  • Held inaugural Sustainability-Focused Supplier Summit at global headquarters.
  • Named 2022 Silver Champion for Supplier Diversity & Inclusion.
  • Nominated and approved member of the steering committee for SPICE (Sustainable Packaging Initiative for CosmEtics).

Responsible Manufacturing

  • Supported The Arbor Day Foundation on three global reforestation projects in Brazil, Madagascar, and the United States.
  • Continued additional water usage analysis with plans to install new water flow meters.
  • Supported The Nature Conservancy’s Global Reefs program through 12 unique impact programs.
  • Joined the UN Global Compact’s Ocean Stewardship Coalition.
  • Richard R. Rogers Manufacturing/R&D facility (R3), announced it passed its OSHA VPP Star Re-Certification with zero findings and recommendations.
  • Received OSHA Star Re-Certification Credentials.

Women’s Empowerment

  • Published “Piloting SDG Localization at the Village Level: A Women-focused Poverty Reduction and Sustainable Development Project in Yunnan Province, China.” Impact Report (Phase 1: 2017-2021).
  • Completed The Women’s Empowerment Principles Gender Gap Analysis Tool as part of our participation in the UN Global Compact Target Gender Equality Accelerator.
  • Advanced women’s leadership in the fishing industry in Mexico through eight projects implemented by The Nature Conservancy.
  • Powered the global launch of a free Entrepreneurship Program in six languages, developed by International Trade Centre SheTrades Initiative.
  • Awarded 14 STEAM grants to young women around the world pursuing dreams in STEAM-related industries.
  • Joined the UN Global Compact Target Gender Equality Program to deepen implementation of the Women’s Empowerment Principles.
  • Submitted survey on the implementation of commitments across the Generation Equality Action Coalitions; findings reflected in UN Women’s Generation Equality Accountability Report 2022.

Social Impact

  • Since 2008, Pink Changing Lives has impacted more than six million women and their families by partnering with over 3,250 organizations and donating over $17 million. In 2022, the cause empowerment program supported over 20 NGOs around the world.
  • Mary Kay and the Mary Kay Ash Foundation grants supported the development and launch of a “GBV Guidance for Development Programs” and its rollout in 10 countries of intervention as well as the establishment of a Community of Practice convening 240 members across 16 countries to date.
  • Mary Kay and the Mary Kay Ash Foundation grants helped the UN Trust Fund change the lives of 54,822 women and girl survivors of violence through 157 GBV projects in 68 countries across five regions including women and girls living with disabilities, internally displaced or refugee women and girls, and Indigenous women and girls.
  • Donated more than $1.3 million to global organizations helping to enrich women’s lives.

About Mary Kay

One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty company in 1963 with one goal: enriching women’s lives. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. As an entrepreneurship development company, Mary Kay is committed to empowering women on their journey to economic independence through education, mentorship, advocacy, networking, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in enriching lives today for a sustainable tomorrow, partnering with organizations from around the world focusing on promoting business excellence, supporting cancer research, advancing gender equality, protecting survivors from domestic abuse, beautifying our communities, and encouraging children to follow their dreams. Learn more at marykayglobal.com, find us on Facebook, Instagram, and LinkedIn or follow us on Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005001/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release

Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to

Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release

About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,

AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release

Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break

Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release

Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti

Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release

Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye